UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
An Open-label follow-on Trial to Assess the Long-term Safety and Efficacy of Oral SPM 927 in Subjects With Diabetic Neuropathy
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 69
- Registration Number
- NCT00861042
A Multi-Centre, Randomized, Double-Blind, Placebo Controlled Pilot Trial to Assess the Efficacy, Safety, and Tolerability of SPM 927 in Subjects With Postherpetic Neuralgia (PHN).
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT00861068
A Trial to Investigate Safety and Efficacy of SPM927 in Painful Diabetic Neuropathy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 119
- Registration Number
- NCT00861445
Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 98
- Registration Number
- NCT00845663
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 131
- Registration Number
- NCT00843778
- Locations
- 🇫🇷
11, Rennes, France
🇫🇷64, Toulouse, France
🇩🇪20, Erlangen, Germany
Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 149
- Registration Number
- NCT00813774
A Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT00800215
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
- First Posted Date
- 2008-10-15
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1005
- Registration Number
- NCT00771927
An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 108
- Registration Number
- NCT00761774
- Locations
- 🇺🇸
281, Fresno, California, United States
🇺🇸285, Peoria, Illinois, United States
🇺🇸245, Sacramento, California, United States
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 168
- Registration Number
- NCT00753454
© Copyright 2024. All Rights Reserved by MedPath